Position in NAMS
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$4,003,934
+$1,007,927 QoQ
Shares Held
118,145
+26.2% QoQ
Ownership
0.099%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#75
of 197 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ALPS ADVISORS INC holds $213,436,831 across 115 Biotechnology names. NAMS ranks #14 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
315,335 | $17,680,833 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
62,523 | $8,298,677 | |
| 3 | CGON |
CG Oncology, Inc.
|
89,218 | $6,338,938 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
97,610 | $5,891,739 | |
| 5 | ORKA |
Oruka Therapeutics, Inc.
|
61,014 | $5,806,702 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
55,281 | $5,388,791 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
93,981 | $5,339,060 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
110,388 | $5,192,651 |
All Filings in NAMS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,003,934 | 118,145 | Shares | Defined | 2026-07-29 | |
| 2026-03-31 | $2,996,007 | 93,596 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $3,259,002 | 92,902 | Shares | Defined | 2026-02-12 | |
| 2025-06-30 | $1,096,578 | 60,551 | Shares | Defined | 2025-08-11 | |
| 2025-03-31 | $1,595,861 | 77,961 | Shares | Defined | 2025-04-30 | |
| 2024-12-31 | $1,920,021 | 74,709 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $1,156,356 | 69,660 | Shares | Defined | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||